Stabilis

Cefazolin sodium



Noms commerciaux

Acef	Italie
Ancef	Etats Unis d'Amérique
Basocef	Allemagne
Biofazolin	Pologne
Brizolina	Espagne
Cecan	Pérou
Cefabiozim	Italie
Cefacidal	Chili, Colombie, Luxembourg, Maroc, Mexique, Pays bas
Cefadin	Inde
Cefamezin	Tunisie
Cefazil	Italie
Cefozin	Turquie
Cromezin	Italie
Eqizolin	Turquie
Fazoplex	Espagne
Intrazolina	Espagne
Kefzol	Autriche, Belgique, Suisse
Kurgan	Espagne
Nefazol	Italie
Recef	Italie
Sefamax	Turquie
Sefazol	Turquie
Sicef	Italie
Tasep	Espagne
Tecfazolina	Espagne
Totacef	Italie
Vifazolin	Grèce
Zepilen	Thaïlande
Zolicef	Autriche
Zolival	Espagne

Stabilité des solutions

		400 mg/ml	-20°C		182			581
		10 mg/ml	25°C		48			418
		400 mg/ml	-20°C		182			581

		10 mg/ml	2-8°C		28				1452
		10 mg/ml	25°C		7				1452
		5 mg/ml	-20°C		182				581
PVC		73,2 mg/ml	-20°C		30				440
PVC		10 mg/ml	-20°C		48				582
PVC		20 mg/ml	-20°C		30				573
PVC		20 mg/ml	5°C		30				3230
PVC		40 mg/ml	5°C		30				3230
PVC		10 mg/ml	4°C		30				656
PVC		20 mg/ml	-20°C		30				576
PVC	Δ® P1 ◆1.5	0,5 mg/ml	25°C		8				2372
PVC	Δ® P1 ◆1.5	0,5 mg/ml	37°C		24				2372
PVC	Δ® P1 ◆1.5	0,5 mg/ml	4°C		14				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	25°C		8				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	37°C		24				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	4°C		14				2372
PVC	Δ® P2 ◆1.5	0,333 mg/ml	25°C		11				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	37°C		24				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	4°C		20				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	4°C		20				1979
PVC	EXTRANEAL	0,5 mg/ml	25°C		7				1805
PVC	EXTRANEAL	0,5 mg/ml	25°C		7				3888
PVC	EXTRANEAL	0,5 mg/ml	37°C		24				1805
PVC	EXTRANEAL	0,5 mg/ml	37°C		24				3888
PVC	EXTRANEAL	0,5 mg/ml	4°C		30				1805
PVC	EXTRANEAL	0,5 mg/ml	4°C		14				3888
POF		10 mg/ml	2-8°C		28				1452
POF		10 mg/ml	25°C		7				1452
EVA		10 mg/ml	23°C		5				1840
EVA		10 mg/ml	4°C		30				1840
PP		100 mg/ml	5°C		30				3230
PP		200 mg/ml	5°C		30				3230
PP		333 mg/ml	-20°C		270				574

		125 mg/ml	20-25°C		24			4634
		50 mg/ml	25°C	?	7			1814
		50 mg/ml	5°C	?	22			1814
PI		12,5 mg/ml	35°C	?	12			4247
PI		12,5 mg/ml	4°C	?	72			4247
PI		25 mg/ml	35°C	?	12			4247
PI		25 mg/ml	4°C	?	72			4247
PI		5 & 40 mg/ml	25°C	?	24			604
PI		5 & 40 mg/ml	4°C		10			604

Stabilité en mélange

		10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		10 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48	418
		10 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml Gentamicin sulfate : 0,8 mg/ml	12	695
		20 mg/ml	25°C		Ranitidine hydrochloride : 0,5 mg/ml	4	2355
		5 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20	630
		10 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml Gentamicin sulfate : 0,8 mg/ml	1	695
		10 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4	2214
	RL	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	0.45	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	Ø	10 mg/ml	25°C		Metronidazole : 5 mg/ml	7	631
	Ø	10 mg/ml	5°C		Metronidazole : 5 mg/ml	12	631
	Ø	10 mg/ml	8°C		Metronidazole : 5 mg/ml	3	671
PVC		5 & 20 mg/ml	23°C-25°C		Aztreonam : 10 & 20 mg/ml	48	426
PVC		5 & 20 mg/ml	4°C-5°C		Aztreonam : 10 & 20 mg/ml	7	426
PVC		5 mg/ml	4°C	?	Tenoxicam : 0,2 mg/ml	72	1951
PVC	EXTRANEAL	0,5 mg/ml	25°C		Ceftazidime : 0,5 mg/ml	2	3888
PVC	EXTRANEAL	0,5 mg/ml	25°C		Gentamicin sulfate : 0,02 mg/ml	4	3888
PVC	EXTRANEAL	0,125 mg/ml	25°C	?	Ceftazidime : 0,125 mg/ml	24	3651
PVC	EXTRANEAL	0,5 mg/ml	37°C		Ceftazidime : 0,5 mg/ml	24	3888

PVC	EXTRANEAL	0,5 mg/ml	37°C		Gentamicin sulfate : 0,02 mg/ml	24	3888
PVC	EXTRANEAL	0,125 mg/ml	37°C	?	Ceftazidime : 0,125 mg/ml	24	3651
PVC	EXTRANEAL	0,125 mg/ml	4°C		Ceftazidime : 0,125 mg/ml	7	3651
PVC	EXTRANEAL	0,5 mg/ml	4°C		Ceftazidime : 0,5 mg/ml	14	3888
PVC	EXTRANEAL	0,5 mg/ml	4°C		Gentamicin sulfate : 0,02 mg/ml	14	3888
POF	∅	10 mg/ml	23°C		Linezolid : 2 mg/ml	3	1659
POF	∅	10 mg/ml	4°C		Linezolid : 2 mg/ml	7	1659

Facteur influençant la stabilité

	[400 mg/ml]				501 1371
					301
	37°C				3651
	37°C				4634

Compatibilités

		Cefazolin sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
		Cefazolin sodium : 20 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Cefazolin sodium : 40 mg/ml Amiodarone hydrochloride : 3 mg/ml		4698
		Cefazolin sodium : 20 mg/ml		1415
		Cefazolin sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
		Cefazolin sodium : 20 mg/ml Alfentanil hydrochloride : 500 µg/ml		3380
		Cefazolin sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefazolin sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefazolin sodium Amikacin sulfate		3549
		Cefazolin sodium : 20 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Cefazolin sodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Cefazolin sodium : 10 mg/ml		4440

		Cefazolin sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Cefazolin sodium : 100 mg/ml	RL	4603
		Cefazolin sodium : 100 mg/ml Alprostadil : 15 µg/ml		3201
		Cefazolin sodium : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Cefazolin sodium : 10 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Cefazolin sodium : 20 mg/ml Aztreonam : 40 mg/ml		99
		Cefazolin sodium : 5 & 20 mg/ml Aztreonam : 10 & 20 mg/ml		426
		Cefazolin sodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713
		Cefazolin sodium Bleomycin sulfate		4154
		Cefazolin sodium : 100 mg/ml Caffeine : 10 mg/ml	∅	3964
		Cefazolin sodium Calcium gluconate		3644
		Cefazolin sodium : 20 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Cefazolin sodium : 100 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Cefazolin sodium : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Cefazolin sodium : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Cefazolin sodium : 10 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Cefazolin sodium : 1 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml		1201
		Cefazolin sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Cefazolin sodium : 20 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Cefazolin sodium Clindamycin phosphate		3526
		Cefazolin sodium : 10 mg/ml Clindamycin phosphate : 9 mg/ml		418
		Cefazolin sodium : 10 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Cefazolin sodium : 41.6 mg/ml Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml		4254

	✓	Cefazolin sodium Daunorubicin/cytarabine liposomale : 0,4 mg/mL	▲	4654
	✓	Cefazolin sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml	▲	1712
	✓	Cefazolin sodium : 200 mg/ml Diltiazem hydrochloride : 1 mg/ml	▲	198
	✓	Cefazolin sodium : 20 & 200 mg/ml Diltiazem hydrochloride : 5 mg/ml	▲	198
	✓	Cefazolin sodium Dimenhydrinate		2087
	✓	Cefazolin sodium : 20 mg/ml Docetaxel : 0.9 mg/ml	◆	1754
	✓	Cefazolin sodium : 100 mg/ml Doxapram hydrochloride : 2 mg/ml	◆	1802
	✓	Cefazolin sodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
1	✗	Cefazolin sodium : 220 mg/ml Erythromycin lactobionate : 20 mg/ml		805
	✓	Cefazolin sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
	✓	Cefazolin sodium : 225 mg/ml		999
	✓	Cefazolin sodium : 20 mg/ml Enalaprilate : 0.05 mg/ml	▲	1315
?	✗	Cefazolin sodium Erythromycin lactobionate		3674
	✓	Cefazolin sodium : 10 mg/ml Esmolol hydrochloride : 10 mg/ml	◆	384
	✓	Cefazolin sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
	✓	Cefazolin sodium : 20 mg/ml Famotidine	◆	397
	✓	Cefazolin sodium : 20 mg/ml Famotidine : 2 mg/ml	▲	215
	✓	Cefazolin sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml		3380
	✓	Cefazolin sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml	◆	63
	✓	Cefazolin sodium : 20 mg/ml Filgrastim : 30 µg/ml	◆	244
	✓	Cefazolin sodium : 20 mg/ml Fluconazole : 2 mg/ml	∅	256
	✓	Cefazolin sodium : 40 mg/ml Fluconazole : 2 mg/ml	▲	496
	✓	Cefazolin sodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml	◆	492
	✓	Cefazolin sodium : 40 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
	✓	Cefazolin sodium : 20 mg/ml Fosfomycin : 30 mg/ml	▲◆	4055
	✓	Cefazolin sodium : 100 mg/ml Gallium nitrate : 1 mg/ml	▲	91

		Cefazolin sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefazolin sodium Gentamicin sulfate		3643
		Cefazolin sodium Gentamicin sulfate		3520
		Cefazolin sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefazolin sodium : 0.333 mg/ml Heparin sodium : 0.667 UI/ml	P2 1.5	1979
		Cefazolin sodium : 10 mg/ml Heparin sodium : 10 & 5000 UI/ml		2037
		Cefazolin sodium : 20 mg/ml Heparin sodium : 50 UI/ml		317
		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		465
		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		472
		Cefazolin sodium : >200 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		226
		Cefazolin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefazolin sodium : 20 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		226
		Cefazolin sodium : 20 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Cefazolin sodium : 20 mg/ml Insulin : 0.2 UI/ml		129
		Cefazolin sodium : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefazolin sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Cefazolin sodium : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Cefazolin sodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cefazolin sodium : 41.6 mg/ml Levetiracetam : 5.21 & 20.83 mg/ml		4254
		Cefazolin sodium : 41.6 mg/ml Levofloxacine : 5 mg/ml		4254
		Cefazolin sodium Lidocaine hydrochloride		499
		Cefazolin sodium : 10 mg/ml Linezolid : 2 mg/ml		1659
		Cefazolin sodium : 20 mg/ml Linezolid : 2 mg/ml		1925
		Cefazolin sodium : 5 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630
		Cefazolin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047

		Cefazolin sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Cefazolin sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefazolin sodium : 10 mg/ml Metronidazole : 5 mg/ml		1035
		Cefazolin sodium : 10 mg/ml Metronidazole : 5 mg/ml		631
		Cefazolin sodium Metronidazole		3594
		Cefazolin sodium : 20 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Cefazolin sodium N-acetylcysteine : 200 mg/ml		3766
		Cefazolin sodium : 20 mg/ml		301
		Cefazolin sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Cefazolin sodium : 20 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Cefazolin sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cefazolin sodium : 10 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Cefazolin sodium Pantoprazole sodium		2090
		Cefazolin sodium : 20 >> 40 mg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Cefazolin sodium : 41.6 mg/ml Pantoprazole sodium : 4 mg/ml		4254
		Cefazolin sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefazolin sodium : 10 mg/ml		1055
		Cefazolin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
		Cefazolin sodium : 41.6 mg/ml Nefopam : 0.16 mg/ml		4254
		Cefazolin sodium : 20 mg/ml Palonosetron hydrochloride : 50 µg/ml		2214
		Cefazolin sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefazolin sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Cefazolin sodium : 0,1 mg/ml	0.225 3.75	4693
		Cefazolin sodium : 10 mg/ml Pethidine hydrochloride : 0,5 mg/ml		111
		Cefazolin sodium : 20 mg/ml Piritramide : 7.5 mg/ml		3380
		Cefazolin sodium : 400 mg/ml		501
		Cefazolin sodium : 400 mg/ml		1371

		Cefazolin sodium : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Cefazolin sodium : 10 mg/ml Promethazine hydrochloride : 25 mg/ml		103
		Cefazolin sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Cefazolin sodium Protamine sulfate		2071
		Cefazolin sodium : 20 mg/ml Ranitidine hydrochloride : 1 mg/ml		2355
		Cefazolin sodium : 20 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Cefazolin sodium Rocuronium bromide		3564
		Cefazolin sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Cefazolin sodium : 20 mg/ml Sargramostim : 10 µg/ml		335
		Cefazolin sodium : 20 mg/ml Sufentanil citrate : 0.005 mg/ml		3380
		Cefazolin sodium : 250 mg/ml Sugammadex : 100 mg/ml		3372
		Cefazolin sodium : 40 mg/ml Tacrolimus : 1000 µg/ml		479
		Cefazolin sodium : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Cefazolin sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
		Cefazolin sodium : 5 mg/ml Tenoxicam : 0,2 mg/ml		1951
		Cefazolin sodium : 20 mg/ml Theophylline : 4 mg/ml		317
		Cefazolin sodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
		Cefazolin sodium : 20 mg/ml Thiotepa : 1 mg/ml		249
		Cefazolin sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefazolin sodium : 1 ; 10 & 200 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Cefazolin sodium : 50 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Cefazolin sodium : 10 >> 200 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefazolin sodium : 10 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Cefazolin sodium : 2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Cefazolin sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Cefazolin sodium : 20 mg/ml Warfarin sodium : 2 mg/ml		315

Voie d'administration

Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
103	Revue	Erickson SH, Ulici D. Incompatibility of cefotetan disodium and promethazine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 1347.
111	Revue	Lee DKT, Wong CY, Wang DP. Stability of cefazolin sodium and meperidine hydrochloride. Am J Health-Syst Pharm 1996 ; 53: 1608,1610.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
226	Revue	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
275	Revue	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
280	Revue	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Revue	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
418	Revue	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
426	Revue	Riley CM, James MJ. Stability of intravenous admixtures containing aztreonam and cefazolin. Am J Hosp Pharm 1986 ; 43: 925-927.
440	Revue	Stiles ML, Tu YH, Allen LV. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 1989 ; 46: 1408-1412.
465	Revue	Wohlford JG, Wright JC, Wilson MR. More information on the visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1990 ; 47: 297-298.
472	Revue	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.

492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
499	Revue	Rockwell K, Burch K. Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. Hosp Pharm 1991 ; 26: 634-635.
501	Revue	Senholzi CS, Kerns MP. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm 1985 ; 42: 129-130.
573	Revue	Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL. Stability of antibiotic admixtures frozen in minibags. Drug Intell Clin Pharm 1977 ; 11: 542-548.
574	Revue	Kleinberg ML, Stauffer GL, Prior RB, Latiolais CJ. Stability of antibiotics frozen and stored in disposable hypodermic syringes. Am J Hosp Pharm 1980 ; 37: 1087-1088.
576	Revue	Holmes CJ, Ausman RK, Walter CW, Kundsin RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357.
581	Revue	Carone SM, Bornstein M, Coleman DL, Thomas PN, Boylan JC. Stability of frozen solutions of cefazolin sodium. Am J Hosp Pharm 1976 ; 33: 639-641.
582	Revue	Tomecko GW, Kleinberg ML, Latiolais CL, Proior RB, Pesko LJ, Jones BC. Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation. Am J Hosp Pharm 1980 ; 37: 211-215.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
630	Revue	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
631	Revue	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
656	Revue	Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions. J Clin Pharm Ther 1996 ; 21: 185-189.
671	Revue	Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture. J Parenter Sci Technol 1993 ; 47: 135-137.
695	Revue	Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. Drug Intell Clin Pharm 1988 ; 22: 873-875.
805	Revue	Oskroba DM, Leissing NC, Trissel LA. An automated process for determining the physical compatibility of drugs. Hosp Pharm 1997 ; 32: 1013-1020.

905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1055	Revue	Faragos S. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. Can J Hosp Pharm 1983 ; 36: 43-52.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1371	Revue	Bornstein M, Templeton RJ. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm 1985 ; 42: 2436.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Revue	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1659	Revue	Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc 2000 ; 40: 509-514.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1805	Revue	Lin YF, Wu CC, Lin SH, Wang DP, Wang CN. Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution. Am J Health-Syst Pharm 2002 ; 59: 2362-2364.
1814	Revue	Gupta VD. Chemical stability of cefazolin sodium after reconstituting in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2003 ; 7, 2: 152-154.
1840	Revue	Xu QA, Trissel LA, Saenz CA et al. Stability of three cephalosporin antibiotics in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: 428-431.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1951	Revue	Wang DP, Lee D, Wang CN. Stability of sodium cefazolin and tenoxicam in 5% dextrose. Chin Pharm J 2001 ; 53: 185-189.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1979	Revue	Wu CC, Wang DP, Wong CY, Lin YF. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm 2002 ; 59: 1537-1538.

1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2037	Revue	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2071	Revue	Ng HP, Koh KF. Precipitation of protamine by cefazolin. Anesth Analg 2002 ; 95: 785.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2214	Revue	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2355	Revue	Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration. Int J Pharm Compound 2000 ; 4, 2: 150-153.
2372	Revue	Nahata MC, Ahalt PA. Stability of cefazolin sodium in peritoneal dialysis solutions Am J Hosp Pharm 1991 ; 48: 291 - 292.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3230	Revue	Donnelly RF. Stability of Cefazolin Sodium in Polypropylene Syringes and Polyvinylchloride Minibags Can J Hosp Pharm 2011 ; 64, 4: 241-245.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.

3380	Revue	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratoire	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3564	Laboratoire	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3651	Revue	Patel R.P, Shastri M.D, Bakkari M, Wanandy T, Jose M.D. Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution. Perit Dial Int 2014 ; 34:212-218
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3888	Revue	Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 2016 ; 36:421-426.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.

4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4247	Revue	Patel R, Jacob J, Sedeeq M, Ming L.C, Wanandy T, Zaidi S.T.R, Peterson G.M. Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices. Clin Ther 2018 ;40,4:664-667
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	Revue	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4693	Revue	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis

Cefazolin sodium



Stabilité des préparations

	16,6 mg Kefzol® (Eli Lilly)	NaCl 0.9% >> 5 ml	4°C		7				2505
	16,6 mg Kefzol® (Eli Lilly)	Tampon acétate pH 4,5 >> 5 ml	4°C		7				2505
	16,6 mg Kefzol® (Eli Lilly)	Tampon acétate pH 5,7 >> 5 ml	4°C		7				2505
	500 mg ® = Cefazolin panpharma	NaCl 0.45% >> 10 mL	4°C		30				2707
	500 mg ® = Cefazolin panpharma	Thiomersal 0,5 mg Glycérine 100 mg Eau ppi >> 10 ml	4°C		30				2707
?	200mg Cefazoline	Eau ppi 1ml Tears Naturale® 3ml	2-8°C		28				3155
?	200mg Cefazoline	Eau ppi 1ml Natear® 3ml	2-8°C		28				3155
?	500 mg Biofazolin®	Tampon citrate pH 6.27 - 161 mOsmol/L	4°C		30				3291
?	500 mg Biofazolin®	Tampon citrate pH 6.27 - 161 mOsmol/L Borate de phenylmercure 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C		30				3291
?	500 mg Biofazolin®	Tampon citrate pH 6.22 - 308 mOsmol/L Alcool polyvinylique η=42.3 mPa.s pH 4.4 - 1.505 g Borate de phenylmercure 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C		30				3291
?	500 mg Biofazolin®	Tampon citrate pH 6.22 - 308 mOsmol/L Alcool polyvinylique η=42.3 mPa.s pH 4.4 - 1.750 g	4°C		30				3291
?	100 mg Biofazolin®	Tampon citrate pH 6.22 - 308 mOsmol/L	4°C		30				3291
?	100 mg Biofazolin®	Tampon citrate pH 6.22 - 308 mOsmol/L Borate de phenylmercure 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C		30				3291
?	100 mg Biofazolin®	Tampon citrate pH 6.11 - 581 mOsmol/L Alcool polyvinylique η=42.3 mPa.s pH 4.4 - 1.950 g	4°C		30				3291

?		100 mg Biofazolin®	Tampon citrate pH 6.11 - 581 mOsmol/L Alcool polyvinylique η=42.3 mPa.s pH 4.4 Borate de phenylmercure 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C	30				3291

Facteur influençant la stabilité

					3155
		40°C			2868
	25°C				2505 2707
	PH >7				2505

Bibliographie

	Type	Source
2505	Revue	Ahmed I, Day P. Stability of cefazolin sodium in various artificial tear solutions and aqueous vehicles Am J Hosp Pharm 1987 ; 44: 2287-2290
2707	Revue	How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY. Stability of cefazolin sodium eye drops J Clin Pharm Ther 1998 ; 23, 1: 41-47.
2868	Revue	Kommanaboyina B, Lindauer RF, Rhodes CT, Grady LT. Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution. Int J Pharm Compound 2000 ; 4, 2: 146-149.
3155	Revue	Rojanarata T, Tankul J, Woranaipinich C, Potawanich P, Plianwong S, Sakulma S, Saehuan C. Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives. J Ocular Pharm Ther 2010 ; 26, 5: 485-490.
3291	Revue	Kodym A, Bilski P, Domanska A, Lukasz Helminiak, Jablonska M, Jachymska A. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method. Acta Pol Pharm 2012 ; 69, 1: 95-105.

Dictionnaire

	Antibiotique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Eau pour préparation injectable		A l'abri de la lumière
	Jour		NaCl 0,9% ou glucose 5%
	Lumière		Heure
	Chlorure de sodium 0,9%		Non précisée
	Glucose 5%	PVC	Polyvinyl chlorure
Δ® P1 1.5	Dianéal® PD1 1.5% glucose (Baxter)	Δ® P1 4.25	Dianéal® PD1 4.25% glucose (Baxter)
Δ® P2 1.5	Dianéal® PD2 1.5% glucose (Baxter)	EXTRANEAL	Extraneal® (Baxter)
POF	Polyolefine	EVA	Ethylène vinyl acétate
	Seringue polypropylène	P I	Elastomère en polyisoprène
	Stabilité en mélange		Solvant
	Molécule	RL	Ringer lactate
0.45	Chlorure de sodium 0,45%	Ø	Aucun
	Facteur influençant la stabilité		Provoque
	Précipitation		Nutrition parentérale (mélange binaire)
	Dégradation		Diminution de la stabilité
	Compatibilités		Compatible
	Précipitation immédiate		Incompatible
	Nutrition parentérale (mélange ternaire)		Instabilité chimique
	Turbidité immédiate		Incompatibilité non précisée
24	Turbidité à 24 heures	1	Turbidité en 1 heure
	Solvant spécifique	1	Précipitation en 1 heure
	Précipitation en 4 heures	2	Précipitation en 2 heures
4	Changement de couleur à 4 heures	0.225 3.75	NaCl 0.225 % + glucose 3.75%

	Voie d’administration		Intraveineuse
	Perfusion intraveineuse		Perfusion continue
	Intramusculaire		Intrapéritonéale
	Bibliographie		Collyre
	Stabilité des préparations		Origine
	Excipient		Flacon injectable
?	Non précisé		Augmentation
	Dictionnaire		